샘플 요청 목록

 카트 문의
시장보고서
상품코드
1798895

세계의 유전자 암 바이오마커 시장

Genetic Cancer Biomarkers
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 276 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

유전자 암 바이오마커 세계 시장은 2030년까지 139억 달러에 달할 전망

2024년에 52억 달러로 추정되는 유전자 암 바이오마커 세계 시장은 2024년부터 2030년까지 CAGR 17.6%로 성장하여 2030년에는 139억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 OMICS는 CAGR 15.5%를 기록하며 분석 기간 종료시에는 66억 달러에 달할 것으로 예측됩니다. 바이오인포매틱스 분야의 성장률은 분석 기간 동안 CAGR 20.2%로 추정됩니다.

미국 시장은 14억 달러, 중국은 CAGR 22.9%로 성장 예측

미국의 유전자 암 바이오마커 시장은 2024년에 14억 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2030년까지 30억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 22.9%를 기록할 것으로 예상됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 13.3%와 15.7%로 예측됩니다. 유럽에서는 독일이 CAGR 약 14.0%로 성장할 것으로 예측됩니다.

세계의 유전자 암 바이오마커 시장 - 주요 동향과 촉진요인 정리

암 진단과 치료에서 유전자 바이오마커가 점점 더 중요해지는 이유는 무엇일까?

유전자 암 바이오마커는 종양의 존재, 진행, 치료 반응성을 밝히는 DNA 또는 RNA 기반 지표입니다. 이러한 바이오마커는 조기 발견, 예후 평가, 치료법 선택, 재발 모니터링에 사용됩니다. 암 연구가 맞춤형 치료 전략으로 발전함에 따라, 유전자 바이오마커는 개별 종양 프로파일에 맞게 치료법을 조정하는 데 필수적인 역할을 합니다. 이 접근법은 약물 투여의 시행착오를 줄이고 치료 결과를 향상시킵니다.

그 적용 범위는 선천성 암 위험의 식별에서 종양 내 후천적 돌연변이 검출에 이르기까지 다양합니다. BRCA1/2, EGFR, KRAS, BRAF와 같은 바이오마커는 유방암, 폐암, 대장암, 흑색종 환자에서 치료 결정의 지침이 됩니다. 액체 생검을 포함한 비침습적 샘플링 기술은 유전자 검사에 대한 접근성을 개선하고 더 빈번한 모니터링을 가능하게 합니다. 암 전문의의 동반진단 채택이 증가하고 있으며, 임상 진료에서 유전자 바이오마커의 역할이 더욱 확립되고 있습니다.

기술 발전이 바이오마커의 검출과 해석을 어떻게 향상시키고 있는가?

차세대 염기서열 분석(NGS) 및 디지털 PCR과 같은 하이스루풋 시퀀싱 기술을 통해 암 관련 변이를 보다 빠르고 정확하게 확인할 수 있게 되었습니다. 이 도구들은 소량의 시료나 열화된 시료에서도 고감도로 여러 유전자를 동시에 분석할 수 있습니다. 계산 플랫폼은 현재 변이 콜링, 돌연변이 주석, 예측 분석을 지원하며, 바이오마커 해석 및 임상적 의사결정을 개선하고 있습니다.

인공지능과 머신러닝의 통합으로 대규모 환자 코호트 전체의 유전체 패턴을 분석함으로써 바이오마커 분류가 정교해지고 있습니다. 클라우드 기반 플랫폼을 통해 익명화된 유전체 데이터 공유가 가능해져 연구개발 및 치료제 개발에 활용되고 있습니다. 실험실에서 개발된 검사 및 FDA 승인 패널을 통해 고형암 및 혈액 악성 종양에 대한 실용적인 바이오마커의 범위가 확대되고 있습니다. 분자진단학이 계속 발전하고 있는 가운데, 바이오인포매틱스와 데이터 통합은 점점 더 복잡해지는 암 유전체학 관리에 필수적인 요소로 자리 잡고 있습니다.

암 분야에서 유전자 바이오마커가 가장 광범위하게 채택된 곳은 어디인가?

병원, 암센터, 기준검사실이 유전자 암 바이오마커 검사의 주요 사용처입니다. 고소득 국가에서는 비소세포폐암, 대장암, 유방암 등 일부 암의 표준 치료 경로에 바이오마커 검사가 포함되어 있습니다. 이 검사는 치료 적격성 평가, 내성 예측, 미세 잔존 병변 모니터링에 사용됩니다. 신흥시장의 종양내과 진료소들도 진단 연구소나 제약사와의 제휴를 통해 바이오마커 검사를 도입하고 있습니다.

바이오 제약사들은 특히 면역치료, 표적 치료제 등의 임상시험에서 환자 계층화에 바이오마커를 활용하고 있습니다. 정밀 종양학 프로그램과 암 등록 프로그램에서는 유전자 프로파일링을 통해 돌연변이 유병률과 치료 결과를 추적하고 있습니다. NGS 플랫폼과 유전 상담에 대한 접근성이 향상됨에 따라 지역 종양 클리닉은 일상적인 워크플로우에 바이오마커 검사를 통합하고 있습니다. 암 치료의 학문적, 상업적 분야 모두에서 채택이 확대되고 있습니다.

유전자 암 바이오마커 시장의 성장 원동력은?

유전자 암 바이오마커 시장의 성장은 분자진단의 통합, 치료의 개별화, 시퀀싱의 용이성과 관련된 몇 가지 요인에 의해 주도되고 있습니다. 암 치료에서 바이오마커 유도 치료의 증가는 종합적인 돌연변이 패널과 동반진단에 대한 수요를 뒷받침하고 있습니다. NGS, 액체 생검, 디지털 PCR의 발전으로 보다 신속하고 최소침습적이며 고감도의 돌연변이 검출이 가능해졌습니다. 바이오마커 식별이 필요한 표적 치료제 개발, 종양학에 초점을 맞춘 임상시험의 확대, 유전자 검사에 대한 상환의 발전도 성장을 뒷받침하고 있습니다. 정밀의료가 암 치료를 혁신하는 가운데, 유전자 바이오마커는 진단의 혁신과 치료의 조정에 있어 핵심적인 역할을 하고 있습니다.

부문

기술(OMICS, 바이오인포매틱스, 기타 기술), 암종(유방암, 전립선암, 백혈병, 기타 암종)

조사 대상 기업 사례

  • Abbott Laboratories
  • Agilent Technologies
  • Amgen Inc.
  • Bio-Rad Laboratories
  • Bio-Techne Corporation
  • BGI Genomics
  • Caris Life Sciences
  • Danaher Corporation(Cepheid, Beckman Coulter)
  • Exact Sciences Corporation
  • Foundation Medicine(Roche)
  • Fulgent Genetics
  • Guardant Health
  • Illumina, Inc.
  • Invitae Corporation
  • Myriad Genetics
  • NeoGenomics Laboratories
  • Qiagen N.V.
  • Roche Diagnostics
  • Thermo Fisher Scientific
  • Veracyte, Inc.

AI 통합

Global Industry Analysts는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 LLM 및 업계 고유의 SLM을 조회하는 일반적인 규범을 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSM 25.09.03

Global Genetic Cancer Biomarkers Market to Reach US$13.9 Billion by 2030

The global market for Genetic Cancer Biomarkers estimated at US$5.2 Billion in the year 2024, is expected to reach US$13.9 Billion by 2030, growing at a CAGR of 17.6% over the analysis period 2024-2030. OMICS, one of the segments analyzed in the report, is expected to record a 15.5% CAGR and reach US$6.6 Billion by the end of the analysis period. Growth in the Bioinformatics segment is estimated at 20.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.4 Billion While China is Forecast to Grow at 22.9% CAGR

The Genetic Cancer Biomarkers market in the U.S. is estimated at US$1.4 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$3.0 Billion by the year 2030 trailing a CAGR of 22.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 13.3% and 15.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 14.0% CAGR.

Global Genetic Cancer Biomarkers Market - Key Trends & Drivers Summarized

Why Are Genetic Biomarkers Gaining Importance in Cancer Diagnosis and Treatment?

Genetic cancer biomarkers are DNA or RNA-based indicators that reveal the presence, progression, or treatment responsiveness of tumors. These biomarkers are used for early detection, prognosis evaluation, therapy selection, and recurrence monitoring. As cancer research evolves toward personalized treatment strategies, genetic biomarkers play an essential role in matching therapies to individual tumor profiles. This approach reduces trial-and-error in drug administration and improves treatment outcomes.

Applications range from identifying inherited cancer risk to detecting acquired mutations within tumors. Biomarkers such as BRCA1/2, EGFR, KRAS, and BRAF help guide therapeutic decisions in breast, lung, colorectal, and melanoma cases. Non-invasive sampling techniques, including liquid biopsies, are improving the accessibility of genetic testing, enabling more frequent monitoring. The growing adoption of companion diagnostics by oncology specialists is further establishing the role of genetic biomarkers in clinical practice.

How Are Technological Advances Enhancing Biomarker Detection and Interpretation?

High-throughput sequencing technologies such as next-generation sequencing (NGS) and digital PCR are enabling faster, more accurate identification of cancer-associated mutations. These tools allow simultaneous analysis of multiple genes with high sensitivity, even from small or degraded samples. Computational platforms now support variant calling, mutation annotation, and predictive analytics, improving biomarker interpretation and clinical decision-making.

Integration of artificial intelligence and machine learning is refining biomarker classification by analyzing genomic patterns across large patient cohorts. Cloud-based platforms enable sharing of anonymized genomic data for research and therapeutic development. Laboratory-developed tests and FDA-approved panels are expanding the range of actionable biomarkers for solid tumors and hematologic malignancies. As molecular diagnostics continue to evolve, bioinformatics and data integration are becoming essential to managing the increasing complexity of cancer genomics.

Where Are Genetic Biomarkers Being Adopted Most Widely in Oncology?

Hospitals, cancer centers, and reference laboratories are the primary users of genetic cancer biomarker testing. In high-income countries, biomarker testing is integrated into standard care pathways for several cancers, including non-small cell lung cancer, colorectal cancer, and breast cancer. Testing is used to assess therapy eligibility, predict resistance, and monitor minimal residual disease. Oncology practices in emerging markets are also adopting biomarker testing through partnerships with diagnostic labs and pharmaceutical companies.

Biopharmaceutical firms rely on biomarkers for patient stratification in clinical trials, especially for immunotherapy and targeted therapies. Precision oncology programs and cancer registries use genetic profiling to track mutation prevalence and treatment outcomes. As access to NGS platforms and genetic counseling improves, community oncology practices are incorporating biomarker testing into routine workflows. Adoption is growing across both academic and commercial segments of cancer care.

What Is Driving Growth in the Genetic Cancer Biomarkers Market?

Growth in the genetic cancer biomarkers market is driven by several factors related to molecular diagnostics integration, therapy personalization, and sequencing accessibility. Increased use of biomarker-guided treatment in oncology care is supporting demand for comprehensive mutation panels and companion diagnostics. Advances in NGS, liquid biopsy, and digital PCR are enabling faster, minimally invasive, and highly sensitive mutation detection. Growth is also supported by the development of targeted drugs that require biomarker identification, expansion of oncology-focused clinical trials, and reimbursement progress for genetic testing. As precision medicine continues to transform cancer care, genetic biomarkers are central to diagnostic innovation and therapeutic alignment.

SCOPE OF STUDY:

The report analyzes the Genetic Cancer Biomarkers market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Technology (OMICS, Bioinformatics, Other Technologies); Cancer Type (Breast Cancer, Prostate Cancer, Leukemia, Other Cancer Types)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

  • Abbott Laboratories
  • Agilent Technologies
  • Amgen Inc.
  • Bio-Rad Laboratories
  • Bio-Techne Corporation
  • BGI Genomics
  • Caris Life Sciences
  • Danaher Corporation (Cepheid, Beckman Coulter)
  • Exact Sciences Corporation
  • Foundation Medicine (Roche)
  • Fulgent Genetics
  • Guardant Health
  • Illumina, Inc.
  • Invitae Corporation
  • Myriad Genetics
  • NeoGenomics Laboratories
  • Qiagen N.V.
  • Roche Diagnostics
  • Thermo Fisher Scientific
  • Veracyte, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Genetic Cancer Biomarkers - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Focus on Personalized and Precision Oncology Drives Adoption of Genetic Biomarkers for Cancer Diagnosis and Treatment Selection
    • Advancements in Next-Generation Sequencing (NGS) and Genomic Profiling Enable High-Throughput Identification of Cancer-Associated Mutations
    • Increased Use of Companion Diagnostics With Targeted Therapies Strengthens Clinical Utility of Genetic Biomarkers
    • Growing Pipeline of Biomarker-Driven Immunotherapies Promotes Demand for Predictive and Prognostic Genetic Testing
    • Integration of Liquid Biopsy Technologies Enhances Early Detection and Monitoring Through Circulating Tumor DNA (ctDNA) Biomarkers
    • Regulatory Approvals and Reimbursement Support for Genomic Testing Boost Market Adoption in Clinical Oncology
    • Rising Incidence of Cancer Globally Expands Screening Programs and Biomarker-Based Risk Stratification Approaches
    • Partnerships Between Biotech Companies and Diagnostic Labs Accelerate Development of Multi-Gene Panels for Tumor Profiling
    • Expansion of Cancer Genomic Databases and AI-Powered Bioinformatics Platforms Enhances Biomarker Discovery and Interpretation
    • Growing Application of Pharmacogenomics in Cancer Treatment Planning Supports Demand for Germline and Somatic Mutation Analysis
    • Increased Role of Biomarkers in Monitoring Minimal Residual Disease (MRD) Strengthens Use Cases Beyond Initial Diagnosis
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Genetic Cancer Biomarkers Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Genetic Cancer Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Genetic Cancer Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for OMICS by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for OMICS by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for OMICS by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Bioinformatics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Bioinformatics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Bioinformatics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Breast Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Prostate Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Leukemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Other Cancer Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Genetic Cancer Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • JAPAN
    • Genetic Cancer Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • CHINA
    • Genetic Cancer Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: China 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: China 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • EUROPE
    • Genetic Cancer Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Genetic Cancer Biomarkers by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Genetic Cancer Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • FRANCE
    • Genetic Cancer Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: France 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: France 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • GERMANY
    • Genetic Cancer Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Genetic Cancer Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Genetic Cancer Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Genetic Cancer Biomarkers by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Genetic Cancer Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Genetic Cancer Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • INDIA
    • Genetic Cancer Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 116: India Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: India 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 119: India Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: India 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Genetic Cancer Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Genetic Cancer Biomarkers by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Genetic Cancer Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Genetic Cancer Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Genetic Cancer Biomarkers by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Genetic Cancer Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • AFRICA
    • Genetic Cancer Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제